Three generic formulations of prostate cancer treatment approved

Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, and Sandoz Inc. have received FDA approval for their generic formulations of bicalutamide tablets, 50 mg.

Bicalutamide is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog in the treatment of stage D2 metastatic prostate cancer.